Lindt opens doors on central London chocolate ‘paradise'
Lindt & Sprungli on Friday opened its flagship central London store, featuring in-house chocolatiers, a recreation of the capital's skyline made entirely of Lindor truffles and a surprise visit from former tennis player Roger Federer.
The shop, which the company has billed as a 'paradise' for chocolate lovers, features the biggest pick and mix of Lindt truffles in the UK as well as ceilings covered with copper mesh cocoa pods.
Fronting the Piccadilly Circus store was a window display of the London skyline, made wholly out of Lindt truffles.
Meanwhile, inside were three classically trained 'master chocolatiers' making fresh chocolate in-store.
It also includes a chocolate barista, serving fresh specialty coffee, hot chocolates, milkshakes and ice cream made live at an in-store chocolate bar.
Swiss sportsman Mr Federer was on the scene to cut the ribbon to officially open what he described as the 'beautiful' store.
The luxury Swiss chocolate-maker, which is marking its 180th anniversary this year, said the first 200 customers to visit the store and spend £10 or more on an item would receive a chocolate-filled gift bag.
The company already has more than a dozen shops and concessions across the UK, including sites in Birmingham, Liverpool and Manchester.
At about 6,000 sq ft – a little over the floorspace of two tennis courts – the upcoming store is the biggest in the UK.
Customers will also be able to put together personalised boxes of Lindor truffles with custom gift tags and ribbons, put together with the help of staff.
Joel Burrows, Lindt's UK and Ireland chief executive, said opening the store is a 'major milestone' for the company.
'To have Roger Federer here for the opening is a truly special moment – he truly embodies the Swiss premium quality that is at the heart of Lindt – and we can't wait for everyone to experience the magic of Lindt in the heart of London.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business of Fashion
17 minutes ago
- Business of Fashion
Art Basel Is Shaping Up to Be a Roll of the Dice
When the Swiss edition of Art Basel opens to VIPs on June 17 (public days are the 19th through the 22nd), Pace gallery's booth will feature a 6-foot-tall Picasso priced 'in excess of' $30 million. Oftentimes, with a work this expensive (and even far less expensive), galleries do their utmost to secure a buyer well before the fair opens, soliciting offers in a phenomenon known as pre-selling. The fair opens, the collector shows up, and the work is officially sold then. But a week before the fair, the gallery had yet to nail down a buyer for the Picasso. 'We have a very good idea about who we think is going to buy it,' says Marc Glimcher, Pace's chief executive officer. 'But we have not 'sort of' sold it. And that is part of the secret family recipe: If you feel confident and you know [the buyer] is going to be there, and you know where they are in their head, do you want to offer it before the fair, or have them bump into it at the fair?' Glimcher is opting for the latter. And he says this dash of serendipity is more common than outsiders might think: 'If I took all of the over $10 million sales that we did in Basel, I'd say that three-quarters of them were a surprise,' he says. ADVERTISEMENT This year ultra-expensive consignments are more of a roll of the dice than usual, several dealers acknowledge. 'I think this insecurity is a bit more on the higher end of the market,' says Thaddaeus Ropac, whose booth at Art Basel will include a Georg Baselitz painting from 1968 priced at about €3 million ($3.45 million), as well as a Robert Rauschenberg work for $1.5 million. 'In the main market, at least from a European perspective, it feels solid,' he continues. 'We've turned now into a buyer's market, where the buyer can say, 'I'm taking my time and thinking about it.'' The overall art market was down 12 percent last year, according to a recent Art Basel and UBS Group AG market report, with $10 million-plus sales at auction falling 39 percent year-over-year by volume and 45 percent by value. The bellwether May auctions in New York didn't help much, as the overall results were lacklustre; at the high end, totals were anaemic. 'It's not easy at the top of the market, but it's not easy at the bottom of the market either,' says the dealer Emmanuel Di Donna, who'll be bringing a $9.5 million triptych by Leonora Carrington, along with a Joan Miró from 1953 priced at about $20 million. 'So for us it's better to focus on the top-end material, as opposed to the rest. There is still a real appetite for museum-quality works when you have the right thing at the right price point.' It's a state of affairs that dealers profess to relish. Ropac says that '2022 was too easy, it went too fast,' meaning 'in times that are more challenging, you concentrate on collectors who are in it for the right motivation, and it cleans out a bit of speculation. I think it's not bad at all. To be honest, I feel rather relaxed.' Glimcher, who's also bringing a Joan Mitchell priced from $15 million to $20 million, acknowledges that 'this is a more questionable time to be selling at the high end,' but he remains sanguine about his gallery's prospects. 'We think some new data is going to come out of Basel,' he says. 'It's going to be the place that will show that there's new energy in the market.' By James Tarmy Learn more: Explainer: Making Sense of Art Basel's New Qatar Fair The world's largest organiser of art fairs will launch its fifth annual event in Doha in February 2026. What does it mean for Art Basel, Qatar and the evolution of an art market desperate for growth opportunities after more than two years of shrinking sales?
Yahoo
5 hours ago
- Yahoo
HUBER+SUHNER opens new facility in Poland
Swiss fibre optic cable manufacturing company Huber+Suhner has inaugurated a new facility in Pisary, Poland. The facility will focus on producing POLATIS optical circuit switches (OCS) to meet the rising demand from artificial intelligence (AI) and data centres. The new site, which spans 3000sqm, will enable the company to capitalise on the growing AI data centre market. Through increasing the manufacturing speed of the POLATIS OCS portfolio, Huber + Suhner can ensure hyperscale operators have the leading-edge technology required to enhance the performance and energy efficiency of data centre architectures and AI compute clusters. Jürgen Walter, Huber+Suhner communication segment chief operating officer, said: 'The opening of our new Pisary facility is a major milestone that aligns with our commitment to innovation and operational excellence in optical networking. Our POLATIS OCS solutions deliver transparent, software-defined dynamic optical connectivity within energy-efficient hyperscale data centres to meet the low loss and latency demands of high-performance AI workloads." 'The Pisary site will enhance our supply of OCS solutions while reflecting our mission for sustainable operations,' says Robert Smith, Huber+Suhner POLATIS managing director. "The facilities include a photovoltaic installation with a capacity of 150 kWp, a mechanical ventilation with heat recovery, and a biological waste treatment plant. A new building management system has also been implemented to support a low carbon footprint." Huber+Suhner, headquartered in Herisau, Switzerland, serves the industry, communications and transportation sectors through the applications of radio frequency, fibre optics and low frequency. The company has a global production network, with subsidiaries and representatives in over 80 countries. "HUBER+SUHNER opens new facility in Poland" was originally created and published by Investment Monitor, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific region. The expanded agreement will see new therapies axatilimab (registered as Niktimvo® in the United States) and retifanlimab (registered as Zynyz® in the U.S. and European Union) added to the current partnered portfolio of Minjuvi® (tafasitamab) and Pemazyre® (pemigatinib). Under the terms of the expanded agreement, Incyte will be responsible for the development, manufacture and supply of both axatilimab and retifanlimab to the region, while ST will have responsibility for regulatory, distribution and local marketing and medical affairs related activities. ST Chief Executive Officer, Mr Carlo Montagner, welcomed the expansion of the partnership agreement with Incyte, a leading global biopharmaceutical company, and the opportunity to bring these important medicines to eligible patients in the local region. "Specialised Therapeutics has partnered with Incyte since 2021 and we are delighted to be extending this successful partnership," he said. "As part of our initial agreement, our teams have worked collaboratively to commercialise Minjuvi, which has been approved for use in Australia, and Pemazyre, which has been approved in Australia and Singapore, and we look forward to expanding the portfolio to help more patients with rare and hard-to-treat conditions." "The addition of axatilimab and retifanlimab to the partnership agreement with Incyte recognises our strong track record of working with local stakeholders to bring innovative medicines to patients where unmet medical needs persist, despite the availability of existing treatments," said Mr Montagner. "Our focus will be on seeking regulatory and reimbursement approval for all four medicines in the region, to ensure equitable access to these treatments are available for patients as soon as practicable." ST anticipates submitting axatilimab and retifanlimab for local regulatory and reimbursement approval in 2025. Incyte CEO, Mr Hervé Hoppenot said the expanded partnership agreement reflected the synergies between the two companies, with a shared goal of improving outcomes for patients with unmet medical needs. "We are pleased to extend our partnership with ST to include axatilimab and retifanlimab," he said. "ST has already demonstrated its ability to navigate complex regional regulatory pathways for Minjuvi and Pemazyre, and we look forward to continuing our work together to make these new therapies available for the oncology community in the Asia-Pacific region." Axatilimab is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody. It was approved by the US Food and Drug Administration (FDA) in August 2024 as a treatment for adults and children with chronic graft-versus-host disease (GVHD) who have received at least two prior treatments (systemic therapy) and require additional treatment.1 Chronic GVHD usually occurs 3 months after a transplant - typically haematopoietic stem cell or bone marrow transplantation, but occasionally also solid organ transplants - where the donor cells ("graft") attack the graft recipient's cells ("host").2 Chronic GVHD can affect all organs, but commonly impacts the skin, mouth, eyes, lungs, stomach, bowel, and liver.2,3 The Phase II clinical trial for axatilimab involved 79 patients from 13 countries, including Australia and Singapore.4 Retifanlimab is an intravenous immune checkpoint (PD-1) inhibitor that has been approved in the US in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy.5 Retifanlimab is also approved in the US6 and Europe7 for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). MCC is a rare and aggressive type of skin cancer, that is often difficult to diagnose due to the lack of specific features to distinguish it from other common skin cancers.8 Australia has the highest incidence of MCC in the world.9 The pivotal Phase II clinical trial of retifanlimab in MCC enrolled 101 chemotherapy-naïve patients from 12 countries, including Australia.10 In addition to MCC, retifanlimab, in combination with chemotherapy, is currently being investigated as a potential therapeutic option in other hard-to-treat cancers, including metastatic non-small cell lung cancer (NSCLC). Ends. About Specialised Therapeutics Founded in 2007, Specialised Therapeutics is the region's largest independent specialty pharmaceutical company, providing new therapies and technologies to patients in Australia, New Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with global pharmaceutical, biotech and diagnostic companies to bring novel healthcare opportunities to patients who are impacted by a range of diseases. ST has built a strong track record of success, navigating complex regulatory, reimbursement and commercialisation environments in its diverse regions. The ST mission is to provide specialty therapies where there is an unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance (WODA). Additional information can be found at About axatilimab (Niktimvo®) Axatilimab-csfr (registered as Niktimvo® in the United States) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the US for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and paediatric patients weighing at least 40 kg (88.2 lbs). In 2016, Syndax licensed exclusive worldwide rights to develop and commercialise axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialisation license agreement for axatilimab in chronic GVHD and any future indications. Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256). Niktimvo is a trademark of other trademarks are the property of their respective owners. About retifanlimab (Zynyz®) Retifanlimab-dlwr (registered as Zynyz® in the United States and European Union) is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), indicated in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy in the U.S. Zynyz is also indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the US. This indication is approved under accelerated approval based on tumour response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Zynyz is marketed by Incyte in the US. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab. Zynyz is a registered trademark of Incyte. References: US FDA. FDA approves axatilimab-csfr for chronic graft-versus-host disease, 14 Aug 2024. Available at: drugs/resources-information-approved-drugs/fda-approves-axatilimab-csfr-chronic-graft-versus-host-disease [Accessed Mar 2025]. The Australasian College of Dermatologists. A-Z of Skin: Graft Versus Host Disease, Nov 2020. Available at: [Accessed Mar 2025]. Leukaemia Foundation Australia. Factsheet: Graft versus host disease, 24 May 2024. Available at: [Accessed Mar 2025]. A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201); NCT04710576. Available at: [Accessed Mar 2025]. FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal. [Accessed May 2025] US FDA. FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma, 22 Mar 2023. Available at: [Accessed Mar 2025]. European Medicines Agency (EMA). Zynyz (retifanlimab): Marketing Authorisation in the European Union (EU), 19 Apr 2024. Available at: [Accessed Mar 2025]. NeuroEndocrine Cancer Australia. Merkel Cell Carcinoma: The Facts, 19 Nov 2023. Available at: [Accessed Mar 2025]. The Australasian College of Dermatologists. A-Z of Skin: Merkel cell carcinoma, Oct 2024. Available at: atoz/merkel-cell-carcinoma/ [Accessed Mar 2025]. Grignani G, et al. Updated Results From POD1UM-201: A Phase 2 Study of Retifanlimab in Patients With Advanced or Metastatic Merkel Cell Carcinoma. Presented at the European Society for Medical Oncology Congress 2023, Madrid, Spain; 20-24 October 2023. View original content to download multimedia: SOURCE Specialised Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
